Core Insights - The company is currently awaiting an important decision regarding the filing for Auvelity and its application for AD agitation, which is a significant topic for stakeholders [1] - The company confirmed that a supplemental New Drug Application (sNDA) was submitted, and they are now waiting to provide further updates on this matter [1] - The expectation is that if the sNDA is accepted, it will undergo a standard review due to the current resource constraints and bandwidth considerations at the FDA, which are independent of the submitted package [2]

Savara (NasdaqGS:SVRA) FY Conference December 02, 2025 02:30 PM ET Company ParticipantsBraden Parker - Chief Commercial OfficerMatt Pauls - CEOConference Call ParticipantsYasmeen Rahimi - Senior Biotech AnalystYasmeen RahimiPiper Sandler Healthcare Conference. My name is Yasmeen Rahimi. I'm a Senior Biotech Analyst at Piper. This is our five-year anniversary, Matt, as we're both at this healthcare conference, and I get to host you for a fireside chat. What can I say? An incredible journey over the five year ...